Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of selective cytotoxic payloads for antibody drug conjugates (ADCs), today announces the appointment of Dr. Robert McLeod as Vice President (VP) Clinical Development.
https://myricxbio.com/wp/wp-content/uploads/2023/09/MyricxBio_Web.svg00proteinbarhttps://myricxbio.com/wp/wp-content/uploads/2023/09/MyricxBio_Web.svgproteinbar2023-09-13 08:49:192023-09-13 08:50:05Myricx Expands its Leadership Team with the Appointment of Dr. Robert McLeod as VP Clinical Development
Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of selective cytotoxic payloads for antibody drug conjugates (ADCs), today announces an antibody license agreement with Biocytogen Pharmaceuticals (Beijing) Co., Ltd (‘Biocytogen’, HKEX: 02315), a global biotech company focusing on the discovery of novel antibody therapeutics.
https://myricxbio.com/wp/wp-content/uploads/2023/09/MyricxBio_Web.svg00proteinbarhttps://myricxbio.com/wp/wp-content/uploads/2023/09/MyricxBio_Web.svgproteinbar2023-09-07 12:02:402023-09-07 12:03:48Myricx Enters into Antibody License Agreement with Biocytogen
New antibody drug conjugate (ADC) programme unveiled, with demonstration of positive pre-clinical proof of concept for Myricx N-myristoyltransferase inhibitors (NMTi) as a completely novel ADC payload (see poster 2635)2 New biology reveals mode of action (MoA) for NMTi via unfolded protein response (UPR) stress pathways in cancer cells (see poster 4871)3 and ability of NMTi […]
https://myricxbio.com/wp/wp-content/uploads/2023/09/MyricxBio_Web.svg00proteinbarhttps://myricxbio.com/wp/wp-content/uploads/2023/09/MyricxBio_Web.svgproteinbar2023-04-17 18:38:152023-04-18 08:11:59Myricx Pharma Presents Positive Pre-clinical PoC Data at AACR for its N-Myristoyltransferase inhibitor (NMTi) ADC Programme Alongside New Biology on Novel MoA for NMTi
Myricx Expands its Leadership Team with the Appointment of Dr. Robert McLeod as VP Clinical Development
Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of selective cytotoxic payloads for antibody drug conjugates (ADCs), today announces the appointment of Dr. Robert McLeod as Vice President (VP) Clinical Development.
Myricx Enters into Antibody License Agreement with Biocytogen
Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of selective cytotoxic payloads for antibody drug conjugates (ADCs), today announces an antibody license agreement with Biocytogen Pharmaceuticals (Beijing) Co., Ltd (‘Biocytogen’, HKEX: 02315), a global biotech company focusing on the discovery of novel antibody therapeutics.
Myricx Pharma Presents Positive Pre-clinical PoC Data at AACR for its N-Myristoyltransferase inhibitor (NMTi) ADC Programme Alongside New Biology on Novel MoA for NMTi
New antibody drug conjugate (ADC) programme unveiled, with demonstration of positive pre-clinical proof of concept for Myricx N-myristoyltransferase inhibitors (NMTi) as a completely novel ADC payload (see poster 2635)2 New biology reveals mode of action (MoA) for NMTi via unfolded protein response (UPR) stress pathways in cancer cells (see poster 4871)3 and ability of NMTi […]